Study of Interferon-γ-Inducible Protein 10 (IP 10) Level as a Diagnostic and Prognostic Marker in Patients on Sofosbuvir and Daclatasvir as Antiviral Therapy of Chronic Hepatitis C.

Document Type : Original Article

Authors

1 Department of Microbiology and Immunology, Faculty of Medicine, Al-Azhar University

2 Department of Hepatology, National Hepatology Institute Al- Menofia University

Abstract

Background: Hepatitis C virus (HCV) belongs to the family Flaviviridae. Elevated plasma levels of the interferonγ-inducible protein 10 (IP 10) is common in HCV infection. Objective: study of IP 10 level as a diagnostic and prognostic marker in patients on sofosbuvir and daclatasvir as antiviral therapy of chronic HCV in comparison with HCV RNA level estimated by PCR. Patients and methods: ELISA estimation of IP 10 serum level and quantitative PCR for hepatitis C RNA virus done for 40 chronic HCV patient before , within and after undergoing antiviral therapy in the form of Sofosbuvir and Daclatasvir ± Ribavirin. In addition, ELISA estimation of IP 10 serum level was done to 20 apparently healthy individuals as a control group. Results: IP 10 serum concentrations were significantly higher in patients than in control group. Sofosbuvir and daclatasvir significantly decreased IP 10 serum level concentrations and this change in concentrations was statistically highly significant. HCV PCR mean were 39×104 ± 78×104 log IU/ml) before start of treatment then declined to undetectable level after one month of treatment till 3 months after the end of treatment. This change in concentrations was statistically significant. Conclusions: IP 10 may be used as a prognostic but not diagnostic marker for treatment efficacy in chronic HCV infected patients subjected to sofosbuvir/daclatasvir combination therapy.

Keywords

The Egyptian Journal of Hospital Medicine
Volume 77, Issue 4
October 2019
Pages 5434-5441

Files

Share

How to cite

Statistics